英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
glitshen查看　glitshen　在百度字典中的解释百度英翻中〔查看〕
glitshen查看　glitshen　在Google字典中的解释Google英翻中〔查看〕
glitshen查看　glitshen　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Apollomics, Inc. - Committed to the discovery and development of . . .
    Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer
  • Pipeline - Apollomics, Inc.
    Apollomics Careers To apply for any of our open positions, please complete the form below and click the Join Apollomics button at the bottom Your information will be reviewed within 1-3 business days
  • Our Company - Apollomics, Inc.
    At Apollomics, we are a purpose-driven company imagining a world without cancer We let science drive our decision making to advance our programs We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve
  • Apollomics, Inc. - Committed to the discovery and development of . . .
    Committed to the discovery and development of oncology combination therapies
  • Apollomics中国 - Apollomics, Inc.
    Apollomics中国 冠科美博是一家生物科技公司，旨在成为抗肿瘤新药开发的全球领导者。 鉴于我们在美国和中国两地均开展业务，我们相信我们具备良好的条件以利用与东西方其他生物科技公司合作的优势，发挥协同作用。
  • Vebreltinib (APL-101) - Apollomics, Inc.
    Apollomics retains worldwide rights to Vebreltinib outside of mainland China, Hong Kong, and Macau Competitive Advantages Targeting multiple cancers with c-Met amplification with or without exon 14 skipping mutation
  • Apollomics China
    Apollomics was founded as a biotechnology company with the vision to become a global leader in the development of novel medicines for cancer patients With operations in both the U S and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and
  • Management - Apollomics, Inc.
    Dr Guo Liang Yu is a co-founder, Executive Director, Chairman and Chief Executive Officer of Apollomics Dr Yu has been one of the key management members of the Company and has been actively involved in its business, strategy and operational management since its establishment
  • Apollomics Inc. , a Late-Stage Clinical Biopharmaceutical Company to be . . .
    Apollomics’ broad pipeline of drug candidates includes late-stage clinical assets for the treatment of patients with difficult-to-treat cancers Apollomics’ mission is to develop assets in critically important areas of unmet need The Company’s leading drug candidates address certain subpopulations within lung cancer and leukemia
  • Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell . . .
    Apollomics is developing vebreltinib as single-agent cancer therapy in a variety of tumor types and actively assessing the potential of vebreltinib in combination with novel therapies Vebreltinib recently received conditional approval from the National Medical Products Administration (NMPA) of China and is currently under clinical





中文字典-英文字典  2005-2009